Subretinal Gene Therapy with scAAV8-hRS1 Shows No Serious Adverse Events: NEJM
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok